Tenon Medical, Inc. TNON
- Market cap
- $3.2M
- P/E
- 0.0×
Follow TNON
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 3,192.00 | 215.60 | 58.45 | 29.75 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | 167,692.00 | 7,672.00 | 552.58 | 204.75 |
High Price
|
|||
| — | — | — | — | — | 10 | 22 | 21 | 27 | 26 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 0 | 0 | 0 | 1 | 3 | 3 | 4 |
Revenue
|
|||
| — | — | — | 66.04% | 58.45% | 65.63% | (92.76%) | 42.38% | 52.21% | 59.79% |
Gross Margin
|
|||
| — | — | — | (1) | (1) | (7) | (19) | (16) | (14) | (13) |
EBT
|
|||
| — | — | — | (1,092.91%) | (1,610.50%) | (4,425.63%) | (2,737.63%) | (532.14%) | (417.24%) | (318.36%) |
EBT Margin
|
|||
| — | — | — | (1) | (1) | (7) | (19) | (16) | (14) | (13) |
Net Income
|
|||
| — | — | — | — | — | 0 | 0 | 0 | 1 | 1 |
Depreciation
|
|||
| — | — | — | 0.05 | 146.00 | 533.33 | 238.28 | 450.46 | 94.44 | 18.67 |
Revenue/Sh
|
|||
| — | — | — | (0.45) | (2,377.17) | (21,846.15) | (6,601.40) | (2,402.80) | (393.71) | (59.44) |
Earnings/Sh
|
|||
| — | — | — | (0.21) | (558.00) | (14,306.67) | (4,146.55) | (1,874.31) | (284.67) | (50.88) |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | 0.00 | (340.00) | (292.07) | (55.54) | (5.36) | (4.84) |
Capex/Sh
|
|||
| — | — | — | (0.21) | (558.00) | (14,646.67) | (4,438.62) | (1,929.85) | (290.03) | (55.72) |
Free CF/Sh
|
|||
| — | — | — | (2.32) | (7,123.00) | (23,043.33) | 2,155.86 | 119.69 | 172.07 | 23.86 |
Book Value/Sh
|
|||
| — | — | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 116.67 | 116.67 | 116.67 | 18.68 | 0.96 | 0.70 | 1.78 |
PS Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 2.07 | 3.63 | 1.03 | 3.58 |
PB Ratio
|
|||
| — | — | — | 96.56 | 96.56 | 96.56 | 7.27 | 0.30 | (1.15) | 0.96 |
EV/Sales
|
|||
| — | — | — | (3.06) | (3.06) | (3.06) | (0.39) | (0.07) | 0.37 | (0.32) |
EV/FCF
|
|||
| — | — | — | 0 | 0 | (4) | (12) | (12) | (10) | (11) |
Op' Cash Flow
|
|||
| — | — | — | — | — | 0 | (1) | 0 | 0 | (1) |
Capex
|
|||
| — | — | — | 0 | 0 | (4) | (13) | (13) | (10) | (12) |
FCF
|
|||
| — | — | — | (1) | (1) | (8) | 7 | 1 | 6 | 4 |
Working Cap'
|
|||
| — | — | — | 1 | 0 | 1 | 1 | — | — | — |
Total Debt
|
|||
| — | — | — | 1 | 0 | (6) | (8) | (2) | (7) | (4) |
Net Debt
|
|||
| — | — | — | (3) | (2) | (7) | 6 | 1 | 6 | 5 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (177.49%) | (145.88%) | (185.82%) | (178.74%) | (168.93%) | (121.89%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (622.66%) |
ROIC
|
|||
| — | — | — | 0.00% | 16.06% | 58.83% | 264.57% | (443.27%) | (912.45%) | (600.05%) |
ROE
|
|||
Tenon Medical, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| XAIR Beyond Air, Inc. | $3.1M | 0.0× | Compare |
| VTAK Catheter Precision, Inc. | $3.0M | 0.0× | Compare |
| NUWE Nuwellis, Inc. | $2.9M | 0.0× | Compare |
| NXL Nexalin Technology, Inc. | $3.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $4.3M | 1.2× | Compare |
| IVF INVO Fertility, Inc | $4.4M | 0.0× | Compare |
| ADGM Adagio Medical Holdings, Inc. | $4.4M | 0.0× | Compare |
| TRIB Trinity Biotech PLC | $4.5M | 0.0× | Compare |
Tenon Medical, Inc. (TNON) key facts
- Tenon Medical, Inc. (TNON) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024.
- As of September 25, 2026, TNON traded at $3.13, a market capitalization of $3.2 million.
- Return on equity was −600.1% and debt-to-equity 0.00.
Tenon Medical, Inc. (TNON) Latest News
9 Sep
Tenon Medical, Inc. announced early repayment of its convertible notes. Early repayment of convertible notes improves the balance sheet and cuts future dilution and interest costs.
31 Aug
WallachBeth Capital announced the closing of a transaction involving Tenon Medical, Inc. (TNON). Closing provides TNON with fresh capital that may support near-term operations but does not signal major strategic shifts.
Tenon Medical closes $3M private placement offering. Private placement raises $3 million in capital affecting financial position.
28 Aug
Tenon Medical priced a $3M private placement offering. Private placement supplies $3M cash that directly affects financial position and share structure.
20 Aug
Tenon Medical (TNON) held its Q2 2026 earnings call to review financial results, operational updates, and outlook. Earnings call details on financials and strategy can significantly alter investor views and stock trajectory.
14 Aug
Tenon Medical Inc (TNON) reported record revenue growth in Q2 2026 earnings call and advanced FDA regulatory matters. Record revenue and FDA progress indicate major financial and regulatory gains likely to shift company trajectory.
13 Aug
Tenon Medical, Inc. held Q2 2026 earnings call detailing quarterly financial results and outlook. Quarterly earnings release offers moderate insight into financial performance and operations.
Tenon Medical, Inc. (TNON) released its financial results for the second quarter of 2026. Quarterly financial results provide performance data that can shift investor sentiment and near-term stock movement.
20 Jul
Tenon Medical, Inc. regained compliance with the Nasdaq Stockholders' Equity Requirement. Avoiding delisting maintains trading access and supports near-term market access without altering core operations.
2 Jul
Tenon Medical receives FDA 510(k) clearance for its Catamaran SI Joint Fusion System. FDA clearance enables commercial launch of the company's core product and supports revenue growth.
1 Jul
Tenon Medical, Inc. closed a $4.2 million public offering facilitated by WallachBeth Capital. The $4.2 million public offering supplies Tenon Medical with additional capital that supports operations and financial position.
Tenon Medical, Inc. closed its $4.2 million public offering. Public offering supplies capital that supports operations and balance sheet without shifting company strategy.
30 Jun
WallachBeth Capital prices Tenon Medical $4.2 million public offering. $4.2 million public offering supplies operating capital to Tenon Medical but dilutes shares.
Tenon Medical, Inc. priced a $4.2 million public offering. The offering supplies capital to Tenon Medical while diluting shareholders and affecting near-term valuation.
13 May
Tenon Medical Inc (TNON) reported record revenue for Q1 2026, driven by strong sales growth and strategic initiatives including expanded market access and new product developments during earnings call. Record revenue and strategic growth directly enhance financial performance and competitive positioning for TNON.
12 May
Tenon Medical, Inc. (TNON) Q1 2026 earnings call summary details first-quarter financial results, operational updates, and future outlook. Q1 earnings summaries reveal financial health and guidance influencing investor sentiment moderately.
Tenon Medical, Inc. (TNON) reported first quarter 2026 financial results, highlighting key revenue, expenses, and operational updates. Quarterly financial results disclosure typically affects short-term market sentiment and stock volatility for small-cap medtech firms.
19 Mar
Tenon Medical Inc (TNON) reported record revenue growth in Q4 2025 earnings call, driven by strong demand for its Superion interspinous fusion device, with full-year revenue up 89% to $5.1 million and strategic moves including FDA breakthrough designation and expanded distribution. Record 89% revenue growth and FDA breakthrough designation position TNON for accelerated market expansion and improved investor sentiment.
Tenon Medical, Inc. (TNON) Q4 2025 earnings call summary details quarterly financial results, operational highlights, and forward-looking guidance. Quarterly earnings summaries reveal financial metrics and strategic updates that significantly shape investor sentiment and stock trajectory.
Tenon Medical (TNON) released Q4 2025 earnings call transcript detailing financial results, operational updates, and future outlook. Q4 earnings transcript discloses financial performance, guidance, and strategic updates that significantly shape investor expectations and stock trajectory.
Tenon Medical, Inc. (TNON) reported fourth quarter and full year 2025 financial results, highlighting key revenue figures, operational updates, and forward-looking guidance. Full-year financial results disclosure represents a major event influencing TNON's stock valuation, investor sentiment, and strategic trajectory.
12 Mar
WallachBeth Capital closed Tenon Medical, Inc.'s private placement of senior original issue discount convertible notes, raising gross proceeds of $4.3 million. Securing $4.3 million in funding through convertible notes provides substantial capital to fuel Tenon Medical's operations and growth trajectory.
Tenon Medical, Inc. (TNON) closed a private placement of senior convertible notes, raising gross proceeds of $4.3 million. Raising $4.3 million via convertible notes provides significant liquidity to fuel Tenon Medical's operations and development efforts.
18 Feb
Tenon Medical strengthens intellectual property portfolio with strategic patent expansion. Strategic patent expansions protect innovations, enhance competitive positioning, and positively influence investor sentiment.
9 Feb
Tenon Medical, Inc. (TNON) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company, potentially influencing its stock performance and investor sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
5 Feb
Tenon Medical, Inc. has announced the date for its fourth quarter and full year 2025 earnings report, reaffirming its expected revenue figures. The company aims to provide insights into its financial performance and operational strategies during this period. The earnings announcement and reaffirmation of expected revenues may moderately influence investor sentiment and financial performance.
28 Jan
Tenon Medical, Inc. has issued a shareholder letter detailing preliminary revenue figures for the fourth quarter and full year of 2025. The company is focused on its growth strategy and aims to enhance shareholder value through its operational initiatives and product offerings. Preliminary revenue figures may influence financial performance but are not expected to fundamentally alter the company's trajectory.
4 Dec
Tenon Medical, Inc. has successfully completed initial cases using its new SImmetry(R)+ SI Joint Fusion System. This innovative system aims to enhance surgical outcomes for patients with sacroiliac joint dysfunction. The company is optimistic about the potential benefits of this technology in improving patient care and expanding its market presence. The introduction of a new surgical system could significantly enhance Tenon Medical's market position and financial performance.
14 Nov
Tenon Medical, Inc. (TNON) reported record revenue in Q3 2025, highlighting significant strategic growth initiatives. The company emphasized its commitment to innovation and expanding market presence, which contributed to the impressive financial results. Management provided insights into future plans aimed at sustaining this momentum and enhancing shareholder value. Record revenue and strategic growth initiatives are likely to significantly impact future performance and investor sentiment.
Tenon Medical, Inc. has successfully closed a $2.85 million At-The-Market Private Investment in Public Equity (PIPE) financing. This financing is expected to provide the company with additional capital to support its growth initiatives and operational needs. The transaction involved the issuance of common stock and warrants, which will help enhance Tenon's financial position. The PIPE financing will provide necessary capital for growth, impacting financial performance moderately.